Depuy Synthes Products, Inc.

Depuy Spine, Inc.

Ethicon, Gmbh

Depuy Products, Inc.

Depuy Mitek, Inc.

Advanced Technologies and Regenerative Medicine, LLC

Laura Brown

Alexander M Harmon

Hassan A Serhan

Thomas M DiMauro

Anna Gosiewska

Mohamed Attawia

Sudhakar Kadiyala

David J Urbahns

Jeffrey C Geesin

Scott Bruder

Sridevi N Dhanaraj

John J Siekierka

Charles J Buckle

Frederick Halperin

Stanko Bodnar

Gregory Collins

Prasanna Malaviya

Alireza Rezania

Agnieszka Seyda

Iksoo Chun

Ian Ross Harris

Mora Carolynne Melican

Pamela Lynn Plouhar

Martin A Reynolds

Carrie H Fang

Melissa Grace

Li Zhang

Jeff Geesin

Jeffery C Geesin

Catherine Smith

Cells derived from postpartum tissue and methods for their isolation and induction to differentiate to cells of a chondrogenic or osteogenic phenotype are provided by the invention. The invention further provides cultures and compositions of the postpartum-derived cells and products such as lysates related thereto. The postpartum-derived cells of the invention and products related thereto have a plethora of uses, including but not limited to research, diagnostic, and therapeutic applications, for example, in the treatment of bone and cartilage conditions such as osteoarthritis.

Method of differentiating umbilical cord tissue into a chondrogenic phenotype

Cells derived from postpartum tissue and products thereof having the potential to support cells of and/or differentiate to cells of a soft tissue lineage, and methods of preparation and use of those postpartum tissue-derived cells, are provided by the invention. The invention also provides methods for the use of such postpartum-derived cells and products related thereto in therapies for conditions of soft tissue.

Soft tissue repair and regeneration using postpartum-derived cells and cell products

The present invention relates to trans-capsularly administering into a diseased joint an inhibitor of p38 MAP kinase or a different therapeutic agent.

Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints

Provided are methods for sterilizing a material comprising a biologically-active agent comprising irradiating said material with ionizing radiation at a dose of about 5 kGy to about 25 kGy while maintaining said material in an atmosphere comprising at least 95% by volume inert gas and at a temperature of about 4&#xb0; C. or lower. Also provided are sterilized materials comprising a biologically-active agent, wherein said materials exhibit substantially the same amount of biological activity as a non-sterilized control.

Methods for sterilizing materials containing biologically active agents

A bioprosthetic device is provided for soft tissue attachment, reinforcement, and or reconstruction. The device comprises a naturally occurring extracellular matrix portion and a three-dimensional synthetic portion. In illustrated embodiments, the naturally occurring extracellular matrix portion comprises layers of small intestine submucosa, and the three-dimensional synthetic portion comprises a foam or a three-dimensional mesh, textile, or felt.

Hybrid biologic-synthetic bioabsorbable scaffolds

The present invention relates to trans-capsularly administering into a diseased joint a high specificity antagonist selected from the group consisting of:

Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints

The present invention relates to administering a doxycycline compound into a diseased intervertebral disc.

Transdiscal administration of cycline compounds

The present invention is directed to tissue-engineering scaffolds containing both a microporous scaffold made from a biocompatible material suitable for use in tissue-engineering scaffolds and a nanofiberous, nanoporous hydrogel formed from a self-assembling peptide, where at least a portion of the hydrogel is disposed within the pores of the microporous scaffold, thus providing tissue-engineering scaffolds having average pore diameters in the nanometer range and that provide both mechanical properties suitable for implantation into a body of a mammal and excellent tissue response once implanted in the body.

Tissue-engineering scaffolds containing self-assembled-peptide hydrogels

The present invention relates to injecting a cycline compound into a diseased intervertebral disc.

The present invention relates to injecting a high affinity antagonist of MMPs into a diseased intervertebral disc.

Transdiscal administration of high affinity anti-MMP inhibitors

Growing community of inventors

Hamilton Square, NJ, United States of America

Laura Brown